05Jun
What We Learned From FDA's Public Hearing On Cannabis
The much-anticipated public hearing last week at the U.S. Food and Drug Administration on cannabis and cannabis-derived compounds drew a wide audience of participants, with strong views on how the FDA should (or should not) regulate the controversial...
By:
Sheppard Mullin Richter & Hampton LLP
Related
In In Re: Appraisal of Jarden Corporation, C.A. No. 12456-VCS (Del. Ch. Jul. 19, 2019), the Delaware...
Read More >
The Internal Revenue Service (IRS) issued Notice 2019-45, expanding the list of preventive care bene...
Read More >
The U.S. Department of Labor Wage and Hour Division is proposing revisions to its model notice of ri...
Read More >
Seyfarth Synopsis: On October 8th, the Supreme Court heard oral argument in a trio of cases that may...
Read More >
With data privacy issues constantly in the news, what do businesses need to know about handling pers...
Read More >
While DOJ had its biggest year in FCPA enforcement, OFAC quietly had a record year in enforcement. ...
Read More >